Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia

Bibliography

• Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006;107(9):2099-107
   PubMed Web of Science ®Google Scholar
• Redaelli A, Lee JM, Stephens JM, Pashos CL. Epidemiology and clinical burden of acute myeloid leukemia. Expert Rev Anticancer Ther 2003;3(5):695-710
   PubMedGoogle Scholar
• Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005;106(4):1154-63
   PubMed Web of Science ®Google Scholar
• Buchner T, Hiddemann W, Berdel WE, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003;21(24):4496-504
   PubMed Web of Science ®Google Scholar
• Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998;351(9104):700-8
   PubMed Web of Science ®Google Scholar
• Wahlin A, Billstrom R, Bjor O, et al. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. Eur J Haematol 2009 [Epub ahead of print; 6 Apr 2009, doi: 10.1111/j.1600-0609. 2009.01256.x]
   PubMedGoogle Scholar
• Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007;109(9):3658-66
   PubMed Web of Science ®Google Scholar
• Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981;304(25):1529-33
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86(5):2041-50
   PubMed Web of Science ®Google Scholar
• Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75(3):555-62
   PubMed Web of Science ®Google Scholar
• Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002;100(6):2132-7
   PubMed Web of Science ®Google Scholar
• Melenhorst JJ, Scheinberg P, Chattopadhyay PK, et al. High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow. Blood 2009;113(10):2238-44
   PubMed Web of Science ®Google Scholar
• Montagna D, Maccario R, Locatelli F, et al. Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. Blood 2006;108(12):3843-50
   PubMed Web of Science ®Google Scholar
• Moretta L, Bottino C, Pende D, et al. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006;18(3):151-8
   PubMed Web of Science ®Google Scholar
• Costello RT, Sivori S, Marcenaro E, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002;99(10):3661-7
   PubMed Web of Science ®Google Scholar
• Fauriat C, Just-Landi S, Mallet F, et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 2007;109(1):323-30
   PubMed Web of Science ®Google Scholar
• Pizzolo G, Trentin L, Vinante F, et al. Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission. Br J Cancer 1988;58(3):368-72
   PubMed Web of Science ®Google Scholar
• Archimbaud E, Bailly M, Dore JF. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance. Br J Haematol 1991;77(3):328-34
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor Natural Killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295(5562):2097-100
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Aversa F, Martelli MF, Velardi A. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev 2006;214:202-18
   PubMed Web of Science ®Google Scholar
• Lotzova E, Savary CA, Herberman RB. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 1987;138(8):2718-27
   PubMed Web of Science ®Google Scholar
• Brune M, Hansson M, Mellqvist UH, et al. NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites. Eur J Haematol 1996;57(4):312-9
   PubMed Web of Science ®Google Scholar
• Lauria F, Raspadori D, Rondelli D, et al. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. Leukemia 1994;8(5):724-8
   PubMed Web of Science ®Google Scholar
• Blaise D, Olive D, Michallet M, et al. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995;345(8958):1144-6
   PubMed Web of Science ®Google Scholar
• Blaise D, Attal M, Reiffers J, et al. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw 2000;11(1):91-8
   PubMed Web of Science ®Google Scholar
• Baer MR, George SL, Caligiuri MA, et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol 2008;26(30):4934-9
   PubMed Web of Science ®Google Scholar
• Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group Phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. Blood 2008;111(3):1044-53
   PubMed Web of Science ®Google Scholar
• Kolitz JE, Hars V, DeAngelo DJ, et al. Phase III trial of immunotherapy with recombinant interleukin-2 (rIL-2) versus observation in patients < 60 years with acute myeloid leukemia (AML) in first remission (CR1): preliminary results from Cancer and Leukemia Group B (CALGB) 19808. ASH Annual Meeting Abstracts 2007;110(11):157
   Google Scholar
• Pautas C, Thomas X, Merabet F, et al. Randomized comparison of standard induction with daunorubicin (DNR) for 3 days vs idarubicin (IDA) for 3 or 4 Days in AML patients aged 50 to 70 and of maintenance with interleukin 2. final analysis of the ALFA 9801 study. ASH Annual Meeting Abstracts 2007;110(11):162
   Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9(3):162-74
   PubMed Web of Science ®Google Scholar
• Mellqvist UH, Hansson M, Brune M, et al. Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells: role of reactive oxygen species and regulation by histamine. Blood 2000;96(5):1961-8
   PubMed Web of Science ®Google Scholar
• Hansson M, Asea A, Ersson U, et al. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol 1996;156(1):42-7
   PubMed Web of Science ®Google Scholar
• Romero AI, Thoren FB, Brune M, Hellstrand K. NKp46 and NKG2D receptor expression in NK cells with CD56dim and CD56bright phenotype: regulation by histamine and reactive oxygen species. Br J Haematol 2006;132(1):91-8
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Asea A, Dahlgren C, Hermodsson S. Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. J Immunol 1994;153(11):4940-7
   PubMed Web of Science ®Google Scholar
• Hansson M, Hermodsson S, Brune M, et al. Histamine protects T cells and natural killer cells against oxidative stress. J Interferon Cytokine Res 1999;19(10):1135-44
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Hermodsson S. Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. Int Arch Allergy Appl Immunol 1990;92(4):379-89
   PubMedGoogle Scholar
• Brune M, Hellstrand K. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. Br J Haematol 1996;92(3):620-6
   PubMed Web of Science ®Google Scholar
• Thoren FB, Romero AI, Hellstrand K. Oxygen radicals induce poly(ADP-ribose) polymerase-dependent cell death in cytotoxic lymphocytes. J Immunol 2006;176(12):7301-7
   PubMed Web of Science ®Google Scholar
• Thoren FB, Romero AI, Hermodsson S, Hellstrand K. The CD16–/CD56bright subset of NK cells is resistant to oxidant-induced cell death. J Immunol 2007;179(2):781-5
   PubMed Web of Science ®Google Scholar
• Betten A, Bylund J, Cristophe T, et al. A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis. J Clin Invest 2001;108(8):1221-8
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Hermodsson S. Histamine H2-receptor-mediated regulation of human natural killer cell activity. J Immunol 1986;137(2):656-60
   PubMed Web of Science ®Google Scholar
• Romero AI, Thoren FB, Brune M, Hellstrand K. Histamine dihydrochloride maintains cytotoxic effector T lymphocyte function and viability under conditions of oxidative stress. ASH Annual Meeting Abstracts 2007;110(11):2309
   Google Scholar
• Hellstrand K, Asea A, Hermodsson S. Role of histamine in natural killer cell-mediated resistance against tumor cells. J Immunol 1990;145(12):4365-70
   PubMed Web of Science ®Google Scholar
• Asemissen AM, Scheibenbogen C, Letsch A, et al. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104). Clin Cancer Res 2005;11(1):290-7
   PubMed Web of Science ®Google Scholar
• Donskov F, Hokland M, Marcussen N, et al. Monocytes and neutrophils as ‘bad guys’ for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma – results from a randomised phase II trial. Br J Cancer 2006;94(2):218-26
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Mellqvist UH, Wallhult E, et al. Histamine and interleukin-2 in acute myelogenous leukemia. Leuk Lymphoma 1997;27(5-6):429-38
   PubMed Web of Science ®Google Scholar
• Brune M, Castaigne S, Catalano J, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006;108(1):88-96
   PubMed Web of Science ®Google Scholar
• Brune M, Romero AI, Hellstrand K. Histamine dihydrochloride and interleukin-2 in acute myeloid leukemia–background and results. Inflamm Res 2009;58(Suppl 1):4-8
   PubMedGoogle Scholar
• Macdonald D, Jiang YZ, Gordon AA, et al. Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: a pilot study. Leuk Res 1990;14(11-12):967-73
   PubMed Web of Science ®Google Scholar
• Blaise D, Attal M, Pico JL, et al. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. Leuk Lymphoma 1997;25(5-6):469-78
   PubMed Web of Science ®Google Scholar
• Spiekermann K, O'Brien S, Estey E. Relapse of acute myelogenous leukemia during low dose interleukin-2 (IL-2) therapy. Phenotypic evolution associated with strong expression of the IL-2 receptor alpha chain. Cancer 1995;75(7):1594-7
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, O'Brien S, et al. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer 1999;85(7):1506-13
   PubMed Web of Science ®Google Scholar
• Wallhult EA, Whisnant JK, Nilsson B, et al. Quality-of-life during remission maintenance immunotherapy in acute myeloid leukemia: a prospective assessment using EORTC QLQ-C30 in a randomized Phase III trial of histamine dihydrochloride plus low-dose interleukin-2. 3rd European Congress of the European Hematology Association; 2008
   Google Scholar